Clinical trial NCT01066494: A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML)
Official title: A Phase IIa Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Adult Patients With Acute Myeloid Leukemia (AML)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Acute Myeloid Leukemia
Keywords: AML
Pgp
MDR
sAML
AS1413
Amonafide
Lead sponsor: Antisoma Research
Sponsor class: INDUSTRY
First posted: 2010-02-10
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A phase IIa study to evaluate the pharmacokinetic and efficacy of amonafide L-malate (AS1413) in combination with cytarabine in treating patients with acute myeloid leukemia (AML)


Eligibility criteria: Inclusion Criteria:

1. Willing and able to provide written informed consent
2. In the opinion of the Investigator able to comply with the study assessments and follow-up
3. New diagnosis of AML (i.e. \>20 % blasts) as defined by the World Health Organization (WHO) classification (Vardiman 2009) or relapsed or refractory AML as defined by the persistence or recurrence of \>5% blasts in bone marrow or peripheral blood following treatment.
4. ECOG Performance status ≤ 2
5. Age \> 18 years and ≤ 70 years
6. Adequate hepatic function as evidenced by the following laboratory tests:

   1. Total serum bilirubin ≤ 1.5 x ULN or direct (conjugated) bilirubin ≤ 1.5 ULN unless attributable to suspected hepatic involvement with AML
   2. Serum AST and ALT ≤ 1.5 x ULN unless attributable to suspected hepatic involvement with AML
7. Adequate renal function as evidenced by serum creatinine ≤ 1.5 x ULN
8. Women of childbearing potential must have a negative serum pregnancy test. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant. This includes women who are using contraceptives or whose sexual partners are either sterile or using contraceptives
9. Left Ventricular Ejection Fraction (LVEF) \> 50%, as determined by multiplegated acquisition scan (MUGA) or echocardiogram (ECHO) within 28 days prior to administration of 1st dose of remission induction chemotherapy

Exclusion Criteria:

1. Unwilling to accept the required per protocol blood and urine sample collection
2. An initial diagnosis of acute promyelocytic leukemia as defined by French- American-British criteria (Bennett 1976) (otherwise known as FAB M3)
3. Clinically active CNS leukemia
4. History of clinically significant allergic reactions attributed to compounds of similar chemical or biological composition to amonafide or cytarabine
5. Pregnant or breast feeding
6. Known HIV positive
7. Known active hepatitis B or C, or any other active liver disease
8. Evidence of pulmonary infection. Patients with evidence of pulmonary infection on screening chest x-ray should have chest computed tomography (CT) prior to starting remission induction therapy to confirm absence or presence of pulmonary infection.
9. Any major surgery or radiation therapy within 30 days prior to study entry
10. Previously received treatment with amonafide
11. Treatment with other investigational agents for any reason within 30 days prior to study entry
12. Prior remission induction therapy for AML within 30 days of starting amonafide therapy
13. Persistent non-hematologic toxicity (other than alopecia) greater than Grade 2 from prior therapy for MDS or AML
14. Serious concomitant illnesses (for example, unstable angina or myocardial infarction or stroke within 3 months prior to study entry, congestive heart

Primary outcomes:
measure: To define the plasma PK Profile of amonafide and metabolite(s)
timeFrame: 1 year
measure: To deine the urniary excretion of amonafide and metabolite(s)
timeFrame: 1 year
measure: To investigate the fecal excretion of amonafide and metabolite(s) in selected patients
timeFrame: 1 year
measure: To evaluate the safety and tolerability of amonafide in combination with cytarabine
timeFrame: 1 year
measure: To evaluate the remission rate
timeFrame: 1 year
Secondary outcomes:
measure: All outcomes are of equal weighting
timeFrame: 1 year
Other outcomes:
Locations:
city: Tbilisi
country: Georgia
facility: Institute of Haematology and Transfusiology
city: Tbilisi
country: Georgia
facility: Medulla - Chemotherapy and Immunotherapy Clinic
city: Tbilisi
country: Georgia
facility: Hema - Haematology and Chemotherapy Clinic
city: Donetsk
country: Ukraine
facility: Institure of URgent adn Recovery Surgery n.a. V.K. gusaka of Academy Medical Science of Ukraine
city: Kiev
country: Ukraine
facility: Kyiv bone Marrow Transplantation Centre
city: Vinnytsya
country: Ukraine
facility: Vinnytsya Regional clinical Hospital
Study officials:
References: